

RADIOPHARM TO BE FEATURED AT B. RILEY SECURITIES HEALTHCARE EVENTS

Sydney, Australia – 8 May 2024 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that it will be featured in a range of healthcare events being hosted by B. Riley Securities during May, covering radiopharma, brain cancer and cell therapies.

The events will be hosted both in New York as well as virtually, with various members of Radiopharm’s board and management team to present on the Company’s technologies and prospects.

Radiopharm CEO and Managing Director Riccardo Canevari will also be part of a panel discussion, ‘New DAWN for Brain Tumors’.

With a large amount of interest in the radiopharmaceutical industry at present, the events are expected to attract a range of US institutional and professional investors.

“We look forward to the opportunity to be featured so prominently throughout this series of events,” said Mr Canevari.

“There is outstanding momentum and M&A activity within the radiopharmaceutical sector recently, and we feel RAD is well positioned to be an emerging player in the field.”

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on the ASX (RAD) since November 2021. The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumour cancers including lung, pancreas and brain. Learn more at [Radiopharmtheranostics.com](https://radiopharmtheranostics.com).

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

**ASX ANNOUNCEMENT
8 MAY 2024**



Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>

InvestorHub – <https://investorhub.radiopharmtheranostics.com/>

